The efficacy of dual sEH/COX-2 inhibition with PTUPB relative to selective inhibition of COX-2 with celecoxib or sEH with t-TUCB independently in reducing eosinophilia and airway inflammation in a clinically relevant model of AAI induced by the fungal allergen A. alternata (Gabriel et al., 2016) was investigated. This evidence concerns the gene EPHX2 and Increased total eosinophil count.